Guadecitabine offers limited advantage over other standards for high-risk AMLJune 26, 2019AMLLeukemia, Myelodysplasia, Transplantation
Rituximab and vemurafenib could challenge frontline chemotherapy for HCLJune 26, 2019Leukemia, Myelodysplasia, Transplantation
‘Robust antitumor immune responses’ observed in pediatric ALLJune 26, 2019ALLPediatricsLeukemia, Myelodysplasia, Transplantation
Risk model could help predict VTE in acute leukemiaJune 26, 2019ThrombosisLeukemia, Myelodysplasia, TransplantationAML
Cell count ratios appear to predict thromboembolism in lymphomaJune 25, 2019ThrombosisLymphoma & Plasma Cell DisordersHodgkin Lymphoma
AML variants before transplant signal need for aggressive therapyJune 25, 2019AMLLeukemia, Myelodysplasia, Transplantation
For tough AML, half respond to selinexor plus chemotherapyJune 25, 2019AMLLeukemia, Myelodysplasia, Transplantation
Hedgehog signaling offers prognostic, therapeutic potential in CLLJune 25, 2019Leukemia, Myelodysplasia, Transplantation
Bispecific CAR T-cell therapy yields complete responses in relapsed/refractory non-Hodgkin lymphomasJune 21, 2019Aggressive LymphomasLymphoma & Plasma Cell DisordersLeukemia, Myelodysplasia, Transplantation
5F9 plus rituximab take a bite out of drug-resistant NHLJune 18, 2019Aggressive LymphomasLymphoma & Plasma Cell Disorders
Durable transfusion independence in MDS with imetelstatJune 18, 2019Myelodysplastic SyndromeLeukemia, Myelodysplasia, Transplantation
